Alberto Borges
Hematology & Oncology · Oakton, VANPI 1962531418
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,216 and has fallen 87.5% since, to $152 in 2023.
Across 171 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$443
- AbbVie$428
- AstraZeneca$419
- Lilly USA, LLC$240
- Esperion Therapeutics, Inc.$205
- Johnson & Johnson$191
- plus $992 from 12 others
What the payments were for
- Food & beverage$2,916100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $443 |
| AbbVie(2 entities) | 28 | $428 |
| AstraZeneca | 22 | $419 |
| Lilly USA, LLC | 12 | $240 |
| Esperion Therapeutics, Inc. | 16 | $205 |
| Johnson & Johnson | 9 | $191 |
| Amgen | 9 | $176 |
| GSK | 8 | $161 |
| Boehringer Ingelheim | 5 | $126 |
| Pfizer | 6 | $121 |
| Redhill Biopharma Inc. | 6 | $108 |
| Amarin Pharma, Inc. | 4 | $86 |
| Merck | 4 | $78 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$2,916 in reported general payments places this provider in the 65th percentile of 293 hematology & oncology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $16,919 |
| Celecoxib | 31 | $2,954 |
| Pioglitazone Hcl | 35 | $447 |
| Omeprazole | 30 | $382 |
| Glipizide ErGlipizide | 28 | $302 |
| Tamsulosin Hcl | 19 | $265 |
| Atorvastatin Calcium | 55 | $245 |
| Levothyroxine Sodium | 33 | $210 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 23 | $192 |
| Naproxen | 15 | $169 |
| Ezetimibe | 21 | $167 |
| Potassium Chloride | 17 | $147 |
| Lisinopril | 11 | $128 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $126 |
| Minoxidil | 17 | $124 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Oakton
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.